Blog

Origin Therapeutics’ Portfolio Company, Clairvoyant, Approved for Phase 2 Psilocybin Therapy Trial; First Clinical Site Initiated in Finland

Oct 19 • 2 min read

Origin Therapeutics Holdings Inc. (CSE: ORIG), an actively managed, psychedelics industry-focused investment issuer, today announced that one of its portfolio companies, Clairvoyant Therapeutics, has received regulatory approval from the Finnish Medicines Agency (FIMEA) to proceed with the company’s Phase 2 clinical trial investigating psilocybin for the treatment of alcohol use disorder (AUD) in Finland. The clinical trial, titled CLA-PSY-201,…

Tim Schlidt is Funding a New Paradigm in Wellbeing – Podcast Episode #22

Oct 19 • 1 min read

On this episode of the Psychedelic Invest Podcast, we welcome Tim Schlidt of Palo Santo. Palo Santo is a leading therapeutics investment fund dedicated to increasing the global supply of clinically effective and accessible healthcare solutions. Tim is a Co-Founder and Partner of the fund, sits on the Board of many psychedelics companies, and recently…

Atai’s Pipeline Update – Weekly Extractions: October 19, 2022

Oct 19 • 1 min read

In this edition of Weekly Extractions, host Adam Tubero provides an analysis on atai Life Science‘s ($ATAI) recent pipeline updates. More specifically, the following developments are discussed: KUR – 101(Mitragynine) INB – 01 (Nasal Spray delivery method) intelGenX’s Oral dissolvable DMT film Below is Atai’s 3-month stock chart straight from their Psychedelic Invest profile page….

What Does the Future of Psychedelics Look Like?: A Mindshifting Moments Special Event

Oct 19 • 1 min read

In this special edition of Mindshifting Moments featuring host Margaret Williamson… Mindshifting Moments extends an invite to Dr. Ivan Casselman of Havn Life and Psychedelic Invest‘s very own Adam Tubero. This Conversation Series answers the question “What does the future of psychedelics look like?” We’ll Be Back To Regularly Scheduled Episodes Next Week We’ve been…

atai Life Sciences Announces Initiation of Phase 1 Proof-of-Concept Clinical Trial for Its Sol-gel Based Direct-to-Brain Drug Delivery Technology

Oct 18 • 3 min read

atai Life Sciences (NASDAQ: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders today announced the initiation of the Phase 1 proof-of-concept (PoC) clinical trial of intranasal INB-01, a sol-gel based, excipient (drug-delivery) technology. This is a Phase 1 two-stage, open-label, randomized study of the safety, tolerability, and effective brain…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482483484485486487488489490491492493494495496497498499500501502503504505506507508509510511512513514515516517518519520521522523524525526527528529530531532533534535536537538